Proteomics

Dataset Information

0

Rational Design of Benzo-Dioxygenated FabH Inhibitors Unveiled by Proteomic Profiling: Broad-Spectrum Antibacterial Activity and In Vivo Therapeutic Efficacy


ABSTRACT: The global escalation of antibiotic-resistant bacterial infections poses a life-threatening challenge to public health, necessitating the urgent development of innovative antibiotics targeting unexploited metabolic vulnerabilities. Through rational design, we developed a series of benzo-dioxygenated FabH inhibitors targeting the bacterial fatty acid biosynthesis pathway. Guided by active-site analysis and pharmacophore-guided optimization, we engineered a Y-shaped scaffold that achieved nanomolar inhibition of FabH (IC50 = 1.90 µM). The lead compound F35 showed broad-spectrum efficacy with MIC values as low as 1.56 µg/mL against Gram-negative and Gram-positive pathogens, outperforming Kanamycin B. Structural analysis revealed key interactions between FabH conserved residues and fluorine-mediated halogen bonding. In vivo assay, F35 accelerated wound closure in S. aureus-infected rodents, demonstrating a favorable biocompatibility. Our study establishes a convergence paradigm that integrates structure design, chemoproteomic identification, and therapeutic development for antibiotics, providing a strategic blueprint to combat multidrug resistance via precision targeting of metabolic chokepoints in bacterial pathogens.

ORGANISM(S): Escherichia Coli

SUBMITTER: Rui Wang  

PROVIDER: PXD064801 | iProX | Tue Jun 10 00:00:00 BST 2025

REPOSITORIES: iProX

Similar Datasets

2020-02-04 | MSV000084899 | MassIVE
2019-10-22 | PXD010174 | Pride
2020-10-30 | GSE139943 | GEO
2025-05-01 | GSE289543 | GEO
2011-12-06 | GSE16887 | GEO
2024-09-02 | BIOMD0000000425 | BioModels
2020-04-02 | MODEL1812040005 | BioModels
2023-08-22 | GSE228489 | GEO
2020-02-04 | MSV000084898 | MassIVE
2011-12-06 | E-GEOD-16887 | biostudies-arrayexpress